Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 347

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

Open access
Ansell, Stephen M., Radford, John, Connors, Joseph M., Długosz-Danecka, Monika, Kim, Won-Seog, Gallamini, Andrea, Ramchandren, Radhakrishnan, Friedberg, Jonathan W., Advani, Ranjana, Hutchings, Martin, Evens, Andrew M., Smolewski, Piotr, Savage, Kerry J., Bartlett, Nancy L., Eom, Hyeon-Seok, Abramson, Jeremy S., Dong, Cassie, Campana, Frank, Fenton, Keenan, Puhlmann, Markus, Straus, David J.·2022·New England Journal of Medicine

Abstract

BACKGROUND: Five-year follow-up in a trial involving patients with previously untreated stage III or IV classic Hodgkin's lymphoma showed long-term progression-free survival benefits with first-line therapy with brentuximab vedotin, a CD30-directed antibody-drug conjugate, plus doxorubicin, vinblastine, and dacarbazine (A+AVD), as compared with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). A planned interim analysis indicated a potential benefit with regard to overall survival; data from a median of 6 years of follow-up are now available. METHODS: We randomly assigned patients in a 1:1 ratio to receive up to six cycles of A+AVD or ABVD. The primary end point, modified progression-free survival, has been reported previously. The key secondary end point was overall survival in the intention-to-treat population. Safety was also assessed. RESULTS: A total of 664 patients were assigned to receive A+AVD and 670 to receive ABVD. At a median follow-up of 73.0 months, 39 patients in the A+AVD group and 64 in the ABVD group had died (hazard ratio, 0.59; 95% confidence interval [CI], 0.40 to 0.88; P = 0.009). The 6-year overall survival estimates were 93.9% (95% CI, 91.6 to 95.5) in the A+AVD group and 89.4% (95% CI, 86.6 to 91.7) in the ABVD group. Progression-free survival was longer with A+AVD than with ABVD (hazard ratio for disease progression or death, 0.68; 95% CI, 0.53 to 0.86). Fewer patients in the A+AVD group than in the ABVD group received subsequent therapy, including transplantation, and fewer second cancers were reported with A+AVD (in 23 vs. 32 patients). Primary prophylaxis with granulocyte colony-stimulating factor was recommended after an increased incidence of febrile neutropenia was observed with A+AVD. More patients had peripheral neuropathy with A+AVD than with ABVD, but most patients in the two groups had resolution or amelioration of the event by the last follow-up. CONCLUSIONS: Patients who received A+AVD for the treatment of stage III or IV Hodgkin's lymphoma had a survival advantage over those who received ABVD. (Funded by Takeda Development Center Americas and Seagen; ECHELON-1 ClinicalTrials.gov number, NCT01712490; EudraCT number, 2011-005450-60.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2206125

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 347

Metadata

Authors
Ansell, S. M., Radford, J., Connors, J. M., Długosz-Danecka, M., Kim, W.-S., Gallamini, A., Ramchandren, R., Friedberg, J. W., Advani, R., Hutchings, M., Evens, A. M., Smolewski, P., Savage, K. J., Bartlett, N. L., Eom, H.-S., Abramson, J. S., Dong, C., Campana, F., Fenton, K., Puhlmann, M., & Straus, D. J.
Venue
New England Journal of Medicine
Published
2022-07-28
Volume
387
Issue
4
Pages
310-320
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4285392390
Cited by
347
References
19
FWCI
39.17
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma. https://app.cochat.ai/papers/10.1056/nejmoa2206125
The paper
Ansell, S. M., Radford, J., Connors, J. M., Długosz-Danecka, M., Kim, W.-S., Gallamini, A., Ramchandren, R., Friedberg, J. W., Advani, R., Hutchings, M., Evens, A. M., Smolewski, P., Savage, K. J., Bartlett, N. L., Eom, H.-S., Abramson, J. S., Dong, C., Campana, F., Fenton, K., . . . Straus, D. J. (2022). Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2206125

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.